These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26095933)

  • 21. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study.
    Jensen MK; Almaas VM; Jacobsson L; Hansen PR; Havndrup O; Aakhus S; Svane B; Hansen TF; Køber L; Endresen K; Eriksson MJ; Jørgensen E; Amlie JP; Gadler F; Bundgaard H
    Circ Cardiovasc Interv; 2011 Jun; 4(3):256-65. PubMed ID: 21540441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J
    Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment.
    Leonardi RA; Kransdorf EP; Simel DL; Wang A
    Circ Cardiovasc Interv; 2010 Apr; 3(2):97-104. PubMed ID: 20197511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry.
    Veselka J; Faber L; Liebregts M; Cooper R; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg J; Stables RH; Jensen MK
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28512112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Sudden Cardiac Arrest After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: ASA-SCARRE Risk Score.
    Veselka J; Liebregts M; Cooper R; Faber L; Januska J; Kashtanov M; Tesarkova KH; Hansen PR; Seggewiss H; Shloydo E; Popov K; Hansvenclova E; Polakova E; Ten Berg J; Stables RH; Jarkovsky J; Bonaventura J
    Am J Cardiol; 2022 Dec; 184():120-126. PubMed ID: 36192196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Sorajja P; Ommen SR; Holmes DR; Dearani JA; Rihal CS; Gersh BJ; Lennon RJ; Nishimura RA
    Circulation; 2012 Nov; 126(20):2374-80. PubMed ID: 23076968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis.
    Schinkel AF; Vriesendorp PA; Sijbrands EJ; Jordaens LJ; ten Cate FJ; Michels M
    Circ Heart Fail; 2012 Sep; 5(5):552-9. PubMed ID: 22821634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy.
    Vriesendorp PA; Liebregts M; Steggerda RC; Schinkel AF; Willems R; Ten Cate FJ; van Cleemput J; Ten Berg JM; Michels M
    JACC Heart Fail; 2014 Dec; 2(6):630-6. PubMed ID: 25447346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
    Maron BJ; Rowin EJ; Casey SA; Link MS; Lesser JR; Chan RH; Garberich RF; Udelson JE; Maron MS
    J Am Coll Cardiol; 2015 May; 65(18):1915-28. PubMed ID: 25953744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.
    Burghardt A; van Buuren F; Dimitriadis Z; Grübbel T; Seggewiss H; Scholtz S; Horstkotte D; Faber L
    Clin Res Cardiol; 2018 Jun; 107(6):479-486. PubMed ID: 29453593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy in the Young and the Elderly.
    Liebregts M; Steggerda RC; Vriesendorp PA; van Velzen H; Schinkel AF; Willems R; van Cleemput J; van den Berg MP; Michels M; ten Berg JM
    JACC Cardiovasc Interv; 2016 Mar; 9(5):463-9. PubMed ID: 26965935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution.
    ten Cate FJ; Soliman OI; Michels M; Theuns DA; de Jong PL; Geleijnse ML; Serruys PW
    Circ Heart Fail; 2010 May; 3(3):362-9. PubMed ID: 20332420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.
    Elliott PM; Gimeno JR; Tomé MT; Shah J; Ward D; Thaman R; Mogensen J; McKenna WJ
    Eur Heart J; 2006 Aug; 27(16):1933-41. PubMed ID: 16754630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of the first patients to undergo transcatheter alcohol septal ablation.
    Lyne JC; Kilpatrick T; Duncan A; Knight CJ; Sigwart U; Fox KM
    Cardiology; 2010; 116(3):168-73. PubMed ID: 20616549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Very late effects of dual chamber pacing therapy for obstructive hypertrophic cardiomyopathy.
    Lucon A; Palud L; Pavin D; Donal E; Behar N; Leclercq C; Mabo P; Daubert JC
    Arch Cardiovasc Dis; 2013; 106(6-7):373-81. PubMed ID: 23806305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
    McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
    Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014.
    Maron BJ; Nishimura RA
    Circulation; 2014 Oct; 130(18):1617-24. PubMed ID: 25462821
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.